Evidence map›Paper›PMID 29631378›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2018

Cytosolic phosphoenolpyruvate carboxykinase as a cataplerotic pathway in the small intestine.

Austin Potts, Aki Uchida, Stanislaw Deja, Eric D Berglund, Blanka Kucejova, Joao A Duarte, Xiaorong Fu, Jeffrey D Browning, Mark A Magnuson, Shawn C Burgess

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. HAntioxidants (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Austin PottsAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center , Dallas, Texas.
Aki UchidaAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center , Dallas, Texas.
Stanislaw DejaCenter for Human Nutrition, The University of Texas Southwestern Medical Center , Dallas, Texas.
Eric D BerglundAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center , Dallas, Texas.
Blanka KucejovaCenter for Human Nutrition, The University of Texas Southwestern Medical Center , Dallas, Texas.
Joao A DuarteAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center , Dallas, Texas.
Xiaorong FuCenter for Human Nutrition, The University of Texas Southwestern Medical Center , Dallas, Texas.
Jeffrey D BrowningDepartment of Clinical Nutrition, The University of Texas Southwestern Medical Center , Dallas, Texas.
Mark A MagnusonDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine , Nashville, Tennessee.
Shawn C BurgessAdvanced Imaging Research Center, The University of Texas Southwestern Medical Center , Dallas, Texas.
The University of Texas Southwestern Medical Center · USAdvanced Imaging Research (United States) · USHumanN (United States) · USVanderbilt University · US

Funding

TARGETED RESPONSIVE MR AND PET AGENTS FOR B-CELL IMAGINGP01DK058398 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MUOIO, DEBORAH M · 2000 to 2016
$26.1M
TR&D 3: Imaging Carbohydrate MetabolismP41EB015908 · NIBIB · UT SOUTHWESTERN MEDICAL CENTER · PI MALLOY, CRAIG R · 2012 to 2021
$10.9M
Factors controlling metabolic flux in the liver - Supplement RevisionR01DK078184 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Shawn C Burgess · 2008 to 2026
$6.8M
Factors Controlling Metabolic Flux in the LiverR56DK078184 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BURGESS, SHAWN C · 2017 to 2017
$243k
NIBIB NIH HHS P41 EB015908NIDDK NIH HHS P01 DK058398NIDDK NIH HHS R01 DK078184NIDDK NIH HHS R56 DK078184
6 · The paper itself

Abstract

Cytosolic phosphoenolpyruvate carboxykinase (PEPCK) is a gluconeogenic enzyme that is highly expressed in the liver and kidney but is also expressed at lower levels in a variety of other tissues where it may play adjunct roles in fatty acid esterification, amino acid metabolism, and/or TCA cycle function. PEPCK is expressed in the enterocytes of the small intestine, but it is unclear whether it supports a gluconeogenic rate sufficient to affect glucose homeostasis. To examine potential roles of intestinal PEPCK, we generated an intestinal PEPCK knockout mouse. Deletion of intestinal PEPCK ablated ex vivo gluconeogenesis but did not significantly affect glycemia in chow, high-fat diet, or streptozotocin-treated mice. In contrast, postprandial triglyceride secretion from the intestine was attenuated in vivo, consistent with a role in fatty acid esterification. Intestinal amino acid profiles and

Indexed as

Intestine, SmallAmino AcidsAnimalsBlood GlucoseCytosolEnergy MetabolismGluconeogenesisGlucoseLipid MetabolismMicePhosphoenolpyruvate Carboxykinase (ATP)Amino AcidsBlood GlucoseGlucosePhosphoenolpyruvate Carboxykinase (ATP)amino acidscataplerosisgluconeogenesisglyceroneogenesissmall intestine

Identifiers

PMID29631378
PMCPMC6139646
OpenAlexW2795650999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.